Sinergia

Synergia Life Sciences is an Indian health-ingredients and nutraceutical company focused on spore probiotics and vitamin K2-7 for the global human health market. The company develops and manufactures clinically documented Bacillus-based probiotic strains, probiotic formulations, and fermentation-derived menaquinone-7 products for use in dietary supplements, functional foods, and related applications. In 2021, Novozymes acquired a majority stake in the business for approximately USD 150 million, positioning Synergia within Novozymes' BioHealth strategy. The company operates manufacturing facilities in India and has supplied products internationally, including branded vitamin K2-7 under MenaquinGold. Overall, Synergia is best understood as a commercial-stage nutraceutical ingredients manufacturer rather than a drug-development biotech with a traditional therapeutic pipeline.